CV Sciences (CVSI) Acquisitions (2013 - 2024)
CV Sciences (CVSI) reported Acquisitions of $4000.0 for Q4 2024, down 97.44% on a YoY basis from $156000.0 in Q1 2024, and up 111.76% sequentially from -$34000.0 in Q3 2024.
CV Sciences (CVSI) Acquisitions (2013 - 2024) Analysis & Trends
CV Sciences (CVSI) has 3 years of Acquisitions data on file, last reported at $4000.0 in Q4 2024.
- For the quarter ending Q4 2024, Acquisitions fell 97.44% year-over-year to $4000.0; the trailing twelve-month figure through Dec 2025 stood at -$30000.0 (down 123.81% YoY), and the FY2024 full-year result was $10000.0, down 93.59% from the prior year.
- Acquisitions climbed to $4000.0 in Q4 2024, from -$34000.0 in the prior quarter.
- In the past five years, Acquisitions ranged from a high of $156000.0 in Q4 2023 to a low of -$34000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acquisitions (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | CV Sciences | 3.74 Mn | 3.43 Mn | 1.56 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 4,000.00 |
| Sep 30, 2024 | -34,000.00 |
| Dec 31, 2023 | 156,000.00 |
| Mar 31, 2013 | 50,775.00 |